Company Encyclopedia
View More
name
Painreform
PRFX.US
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
4.513 T
PRFX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Painreform Commences Development For Ocuring™-K Phase II Trial

    PainReform Ltd :PAINREFORM COMMENCES DEVELOPMENT FOR OCURING™-K PHASE II TRIAL, LAYERBIO’S DROP-LESS SUSTAINED-RELEASE OCULAR THERAPY

    Reuters·
    US
    PRFX
    +0.98%
    Reuters·
    US
    PRFX
    +0.98%

    PainReform Advances Drop-Less OcuRing-K Therapy Toward Phase II Trial

    PainReform Ltd. is advancing its drop-less OcuRing-K therapy, designed for post-cataract pain and inflammation, toward a Phase II clinical trial in the U.S. in collaboration with LayerBio. The therapy aims to provide consistent control with lower drug exposure than traditional eye drops. Future updates will follow as the program progresses.

    Reuters·
    US
    PRFX
    +0.98%
    Reuters·
    US
    PRFX
    +0.98%

    PainReform Ltd. Announces Date for Upcoming Annual General Meeting of Shareholders

    PainReform Ltd. will hold its Annual General Meeting of Shareholders on December 30, 2025, in Tel Aviv, Israel. Shareholders will vote on the re-election of Dr. Ehud Geller, a name change to PRF Ltd., and a grant of options to Asaf Shavit. The meeting's proposals are subject to regulatory approval.

    Reuters·
    US
    PRFX
    +0.98%
    Reuters·
    US
    PRFX
    +0.98%

    PainReform’s DeepSolar Advances AI Reporting Engine for Solar Assets

    PainReform Ltd. announced on November 12, 2025, that its solar energy unit, DeepSolar, has developed an AI-driven automated reporting engine for solar asset analysis. This engine aims to streamline performance report production, enhancing decision-making and asset performance. However, TipRanks’ AI Analyst rates PRFX as Underperform due to significant financial challenges, including lack of revenue and persistent losses, leading to a negative P/E ratio. PainReform focuses on AI-driven energy optimization and therapeutic reformulation, reflecting its commitment to healthcare and renewable energy sectors.

    Tip Ranks·
    US
    PRFX
    +0.98%
    Tip Ranks·
    US
    PRFX
    +0.98%

    PainReform shares are trading higher after the company announced its solar energy business unit was recently featured in a Watchlist Interview produced in collaboration with The Market Link, highlighting its participation in the NVIDIA Connect program.

    benzinga_article·
    US
    PRFX
    +0.98%
    benzinga_article·
    US
    PRFX
    +0.98%
    © 2025 Longbridge｜Disclaimer